Form 4: Senti Biosciences Director Acquires Stock Options
SEC Form 4 Filing
Director Omid Farokhzad acquired 62,500 stock options in Senti Biosciences on July 10, 2024.
Summary
- Omid Farokhzad, a director of Senti Biosciences, acquired 62,500 stock options on July 10, 2024.
- The exercise price of these options is $0.31.
- The options vest upon the earlier of the first anniversary of the grant date or the date of the 2025 Annual Meeting, contingent on continued service.
- The expiration date for these options is July 9, 2034.
- Following the transaction, Farokhzad directly owns 62,500 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, indicating a standard transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a standard disclosure related to insider transactions, common in publicly traded companies.
Stakeholder Impact
- The acquisition of stock options by a director may signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/10/2024 | Date of transaction: Director Omid Farokhzad acquired stock options. |
| 07/09/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.